Testosterone Replacement Therapy Cost: A Complete 2025 Breakdown

For most men who suspect their testosterone is low, the first question their doctor answers is medical. The second question, which often determines whether they follow through, is financial. Testosterone replacement therapy cost varies so dramatically across delivery methods, care settings, and insurance arrangements that two men receiving clinically identical treatment can pay anywhere from $30 to over $500 per month. Understanding why requires unpacking a system where pharmacy pricing, compounding regulations, telehealth infrastructure, and insurance adjudication all intersect, often in ways that work against the patient.

Testosterone deficiency, or hypogonadism, affects an estimated 2 to 4 percent of men by strict clinical criteria, though functional low-testosterone symptoms are reported far more broadly as men age past 40 [1]. The clinical consequences extend well beyond libido: sustained low testosterone is associated with accelerated muscle loss, increased visceral fat, impaired insulin sensitivity, reduced bone density, and cognitive changes that compound over decades [2]. From a longevity standpoint, the question is not merely symptomatic relief but whether restoring testosterone to an optimal physiological range alters the trajectory of metabolic and musculoskeletal aging. That question makes the cost of treatment a public health issue, not just a personal finance one.

This article provides a transparent, method-by-method breakdown of what TRT actually costs in 2025, including the variables that most pricing guides omit: the cost of monitoring labs, the fine print on insurance coverage, and the structural price advantages that telehealth platforms have created by removing overhead that traditional urology and endocrinology practices cannot.

Why Testosterone Replacement Therapy Cost Varies So Widely

The sticker price of any TRT program is not the price of a drug. It is the aggregate cost of a drug, a delivery mechanism, the prescribing infrastructure, the compounding or manufacturing channel, and ongoing laboratory monitoring. Each of those components can be sourced at wildly different price points depending on where the patient enters the system.

Delivery method is the single largest driver of cost variation. Testosterone is a small lipophilic molecule that can be administered by injection, transdermal gel, adhesive patch, subcutaneous pellet implant, or oral softgel. Each route has a different pharmacokinetic profile, meaning the pattern by which testosterone enters the bloodstream and reaches peak and trough levels differs meaningfully [3]. These pharmacokinetic differences affect both clinical outcomes and, less obviously, cost. Injectable testosterone cypionate, for instance, is off-patent and manufactured generically at commodity scale, which drives its pharmaceutical cost to a few dollars per milliliter. Testosterone pellets, by contrast, involve a minor surgical procedure requiring a clinician's time, a sterile facility, and a consumable implant, all of which accumulate into a procedure-based fee that can reach $600 to $1,000 per insertion.

The care setting is the second major variable. A traditional endocrinology or urology practice carries overhead that includes office space, administrative staff, billing departments, and the regulatory costs of operating a brick-and-mortar medical facility. A telehealth longevity clinic operating asynchronously or via video consultation eliminates many of those fixed costs and passes a portion of the savings directly to patients through lower consultation and management fees. The trade-off, in some cases, is reduced in-person access, but for stable patients on a well-established protocol, that trade-off is often clinically immaterial.

Insurance coverage adds another layer of unpredictability. Most commercial health plans cover FDA-approved testosterone formulations when hypogonadism is diagnosed with documented lab confirmation, typically two morning total testosterone measurements below the lab's reference range, often cited as 300 ng/dL [1]. In practice, coverage decisions vary by plan, formulary tier, and whether the prescribing physician is in-network. Some plans cover injections but not gels. Others require prior authorization that can take weeks and still be denied. The result is that insurance coverage, when it exists, can reduce out-of-pocket cost to near zero, but the path to coverage is neither guaranteed nor predictable.

Testosterone Injections: The Most Cost-Effective Delivery Method

Injectable testosterone has been the clinical workhorse of TRT for more than half a century, and its price reflects that maturity. Testosterone cypionate and testosterone enanthate, the two most common injectable esters used in the United States, are available as FDA-approved generics and, separately, through compounding pharmacies that produce customized concentrations for prescribers who want flexibility in dosing.

The branded injectable testosterone cypionate, available in a 200 mg/mL vial, has a retail price that ranges from roughly $30 to $90 per 10 mL vial without insurance, depending on the pharmacy. A standard TRT protocol using weekly injections of 100 mg typically consumes 1 mL per week, or approximately one 10 mL vial every 10 weeks. At that consumption rate, the annual pharmaceutical cost of injectable TRT sits in the range of $150 to $450, making it by far the least expensive delivery mechanism available [4].

Compounded testosterone cypionate, sourced from a 503B outsourcing facility, can be even less expensive on a per-dose basis, often arriving in larger vials at concentrations like 200 mg/mL or custom concentrations. Some compounding pharmacies supply 30 mL vials for $60 to $80, which at a 100 mg weekly dose represents nearly a seven-month supply for under $100. These compounded products are not FDA-approved as finished drug products, but 503B-outsourced compounds are manufactured under FDA oversight and Good Manufacturing Practice standards [5].

The total cost of injectable TRT, however, must include the needles and syringes used for self-injection, alcohol swabs, and any supplies for intramuscular or subcutaneous administration. These consumables typically add $10 to $30 per month. Subcutaneous injection, which uses smaller insulin-gauge needles, has grown in popularity due to reduced injection discomfort and is supported by evidence showing comparable testosterone bioavailability to intramuscular injection [5].

Injectable testosterone cypionate remains the most cost-effective delivery method available, with an annual pharmaceutical cost that can be as low as $150 when sourced through compounding pharmacies.

Telehealth platforms like Healthspan's Testosterone Cypionate program provide access to injectable TRT with the convenience of physician oversight, prescription management, and laboratory coordination without requiring the patient to visit a specialist's office. This model is particularly well-suited to men who have already confirmed their diagnosis and are seeking a stable, long-term protocol managed efficiently.

Testosterone Gels and Topical Creams: Convenience at a Premium

Transdermal testosterone, applied as a gel or cream to the skin's surface, was introduced commercially with the launch of AndroGel in 2000 and rapidly became the most prescribed TRT formulation in the United States by volume. The appeal is clinical and practical: daily application avoids injections, produces relatively stable serum testosterone levels without the peak-and-trough fluctuation of weekly injections, and is familiar to patients who use other topical medications [3].

The cost, however, is substantially higher than injectables. Branded testosterone gels such as AndroGel 1.62% or Testim carry retail prices ranging from $400 to $600 per month without insurance. Generic 1% testosterone gel, which became available after AndroGel's patent expiration, is considerably less expensive at $50 to $150 per month retail, though pricing varies significantly by pharmacy and region. Good Rx and similar discount programs frequently bring generic gel costs into the $30 to $80 per month range at major pharmacy chains.

Compounded testosterone cream, available through compounding pharmacies in custom concentrations typically ranging from 10% to 20% by weight, offers another pricing tier. A 30-day supply of compounded testosterone cream can cost $40 to $120 depending on the concentration and the compounding pharmacy used. The higher concentration allowed in compounded formulations means a smaller applied volume achieves the target dose, which some patients find more convenient. Healthspan's Testosterone Topical Cream is one such option, providing physician-managed topical therapy with straightforward ongoing care.

Topical testosterone gel is also available in a pre-filled pump formulation, Androderm, which uses a patch-free design and delivers metered doses. The pricing structure is similar to other branded gels. Absorption variability is an important clinical consideration for topical testosterone: application site, skin thickness, perspiration, and clothing coverage all affect how much testosterone actually enters systemic circulation, which means some patients require higher doses to achieve target serum levels, further affecting cost [3].

The critical safety consideration that affects household cost of topical testosterone is transfer risk. Testosterone can be transferred to women and children through skin contact with application sites, which requires careful attention to application timing, site coverage, and hand-washing protocols. Inadvertent transfer causing virilization in female partners and children has been documented in clinical literature and represents a non-financial but practically significant cost of this delivery method [3].

Testosterone Gel (Brand-Name) vs. Compounded Topical: What You Actually Pay

The divergence between brand-name and compounded topical costs is wide enough to warrant specific attention. For a man prescribed AndroGel 1.62% at the typical starting dose of 40.5 mg per day (two pump actuations), the cash price at a retail pharmacy without insurance or a discount card is approximately $500 per month, or $6,000 annually. With a GoodRx coupon, that same prescription often falls to $80 to $150 per month at select pharmacies. With commercial insurance covering the branded formulation, the patient may pay a tier-3 specialty copay of $50 to $100 per month, or far less with a manufacturer copay card.

A compounded testosterone cream at a therapeutically equivalent dose from a licensed 503A compounding pharmacy typically costs $60 to $100 per month. The clinical evidence does not support a meaningful bioavailability advantage for the branded gel over a well-formulated compounded cream, though individual absorption variability makes direct comparison imprecise [3]. The price gap suggests that most patients who are paying full retail for branded testosterone gel could achieve equivalent outcomes at a fraction of the cost through either a generic formulation or a compounded alternative, if their prescriber is open to it. Healthspan's Testosterone Gel program offers a telehealth-managed path to topical therapy that keeps costs transparent from the outset.

Testosterone Patches: Clinical Consistency, Middling Cost

The Androderm transdermal patch delivers testosterone through an adhesive reservoir worn against the skin, typically on the back, abdomen, upper arm, or thigh, and replaced nightly. The patch design is engineered to produce a diurnal testosterone profile that approximates the natural circadian pattern of testosterone secretion, with higher levels in the morning and lower levels by evening [3]. From an endocrinological standpoint, this is a meaningful pharmacokinetic advantage over once-weekly injections, which produce supraphysiologic peaks in the first 48 hours followed by a trough by day six or seven.

The retail cost of the Androderm patch runs approximately $350 to $500 per month without insurance for the standard 2 mg or 4 mg formulation. Generic transdermal testosterone patch options have entered the market and brought prices somewhat lower, but patches as a category remain more expensive than generic gels and substantially more expensive than injectables. GoodRx pricing for generic testosterone patches is typically in the $80 to $200 range per month at cooperating pharmacies.

Skin irritation is the most commonly cited tolerability issue with testosterone patches, affecting a significant minority of users at the application site. In studies, local skin reactions including erythema, itching, and contact dermatitis led to discontinuation in roughly 10 to 15 percent of patch users [3]. For men who experience persistent skin reactions, the practical cost includes either rotating application sites aggressively or switching to a different delivery method, adding to the overall cost calculus.

Testosterone Pellets: High Upfront Cost, Infrequent Dosing

Subcutaneous testosterone pellets represent a fundamentally different cost model. Small pellets made of crystalline testosterone, each roughly the size of a grain of rice, are implanted beneath the skin of the upper buttock during a brief in-office procedure performed under local anesthesia. The pellets dissolve slowly over three to six months, releasing testosterone at a relatively consistent rate without any daily or weekly patient action required [3].

The procedure-based pricing model for pellet therapy means costs are expressed per insertion rather than per month. A single pellet insertion typically costs between $500 and $1,000 in total, which includes the cost of the pellets themselves, the physician's time, the procedural supplies, and the facility fee. At two to four insertions per year, the annual cost of pellet-based TRT ranges from roughly $1,000 to $4,000. This is higher than injectables or generic gels on an absolute annual basis, though some patients weight the convenience of a six-month hands-off protocol heavily enough to justify the premium.

Insurance coverage for testosterone pellets is inconsistent. Many commercial plans do not cover pellet insertion as a distinct procedure, and even when testosterone therapy itself is covered, the implantation is often denied as a non-preferred method when less expensive alternatives exist. Out-of-pocket pellet costs are therefore relatively predictable: nearly all pellet patients pay cash.

A further practical consideration is dose titration. Once pellets are implanted, the dose cannot be adjusted until the next insertion cycle. If a patient develops polycythemia, an excess of red blood cells that is a known dose-dependent risk of testosterone therapy, or experiences symptoms of overdose, the pellets must be removed surgically or the patient must wait for natural dissolution [4]. This inflexibility can carry a clinical cost that does not appear on any invoice.

Oral Testosterone: The Newest Delivery Method and Its Cost

The FDA approval of testosterone undecanoate (Jatenzo) in 2019, followed by testosterone undecanoate in a different capsule formulation (Tlando) in 2022, introduced a genuinely viable oral testosterone option for men who categorically prefer not to inject or apply topical preparations. Earlier oral testosterone preparations were hepatotoxic because they required first-pass liver metabolism; testosterone undecanoate is absorbed via the lymphatic route, bypassing the liver and avoiding that toxicity profile [3].

The retail cost of oral testosterone undecanoate is currently among the highest of all delivery methods. Jatenzo is listed at approximately $700 to $900 per month without insurance. Generic oral testosterone formulations are not yet widely available. Insurance coverage follows the same general pattern as other branded testosterone products: covered for documented hypogonadism on approved formularies, with significant variability by plan. For most patients, oral testosterone is only financially accessible if their insurance covers it or if manufacturer assistance programs apply to their situation.

The clinical trade-off involves meal requirements: oral testosterone undecanoate must be taken twice daily with a meal containing at least 30 grams of fat to ensure adequate absorption. Adherence to this requirement directly affects the therapeutic outcome, and forgetting a meal requirement is a more realistic failure mode than forgetting a weekly injection for many patients. These practical considerations make oral testosterone a niche option despite its appeal in principle.

The Hidden Costs of TRT: Labs, Monitoring, and Management Fees

Any pricing comparison that considers only the drug itself is incomplete. Responsible testosterone replacement therapy requires regular laboratory monitoring to ensure therapeutic efficacy and to screen for known risks, and those labs carry real costs that vary depending on how care is structured.

The minimum recommended monitoring panel for men on TRT includes total testosterone (ideally timed to midpoint of the dosing interval for injectables), hematocrit or hemoglobin, and prostate-specific antigen [1]. The rationale for hematocrit monitoring is that testosterone stimulates erythropoiesis, the production of red blood cells, through increased renal erythropoietin secretion. Polycythemia, defined as hematocrit above 54 percent in most guidelines, increases blood viscosity and thrombosis risk and requires dose reduction or therapeutic phlebotomy to manage [1].

The minimum monitoring panel for men on TRT, including testosterone levels, hematocrit, and PSA, is not optional, and its cost belongs in any honest accounting of what TRT requires.

PSA monitoring is important because testosterone therapy raises circulating androgens, and prostate cancer is androgen-sensitive. Current evidence does not support the historical concern that TRT causes prostate cancer in men with normal prostates, but the guidelines recommend PSA measurement at baseline and periodically thereafter to identify pre-existing prostate disease that might be clinically unmasked by treatment [1].

Many comprehensive programs also recommend monitoring estradiol, as testosterone aromatizes to estrogen in peripheral tissues, and some men on TRT develop elevated estradiol levels that can cause gynecomastia or fluid retention. LH and FSH monitoring is relevant for men who are also concerned about preserving fertility, as exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis and reduces sperm production [2]. For men who want to maintain fertility, enclomiphene therapy, which stimulates endogenous testosterone production rather than replacing it exogenously, represents an alternative that avoids this suppression. Healthspan's Enclomiphene protocol addresses this specific clinical scenario.

The out-of-pocket cost of laboratory testing depends heavily on insurance coverage and on whether labs are ordered through a traditional in-network physician, a concierge service, or a direct-to-consumer lab platform. Without insurance, a comprehensive TRT monitoring panel drawn at a commercial lab like Quest or LabCorp can cost $150 to $400 per draw, depending on which tests are included. With insurance, the same panel may cost $0 to $50 after negotiated rates and deductibles. Direct-to-consumer platforms offer testosterone and hormone panels for $50 to $150, though these may not include all clinically recommended analytes.

Monitoring frequency should be every three to six months for the first year of TRT and then annually once levels and hematocrit are stable [1]. Adding the cost of two to four lab draws per year to the pharmaceutical cost meaningfully changes the total cost picture, particularly for patients without insurance.

Physician management fees vary by care setting. A traditional specialist typically charges a new patient visit fee of $200 to $500 and follow-up visit fees of $100 to $250 per appointment. A telehealth platform often bundles consultation and management into a monthly program fee that ranges from $30 to $150 per month, inclusive of provider access and prescription management. Over a full year, the management fee differential between a specialty office and a telehealth platform can easily exceed $1,000.

Insurance Coverage for TRT: What the Fine Print Actually Says

Commercial health insurance covers FDA-approved testosterone formulations for diagnosed hypogonadism, but coverage details vary so substantially by plan that generalization is unreliable. The following summary reflects patterns across major commercial insurers rather than any specific plan's terms.

Generic testosterone cypionate injection is the most consistently covered formulation across commercial plans. Because its cost to the insurer is low, prior authorization requirements are often less stringent than for branded formulations. When covered, patient copays for generic injectables can be as low as $5 to $20 per fill at preferred pharmacies.

Branded testosterone gels, including AndroGel and Testim, typically require step therapy, meaning the insurer requires documentation that the patient has tried and failed a generic formulation before covering the branded option. Copays for covered branded gels range from $30 to $100 per month on Tier 3, or higher if the plan classifies them as specialty medications.

Testosterone pellet insertion is frequently excluded from coverage as a non-preferred treatment method. When plans do cover pellets, they typically require prior authorization with documentation of clinical necessity and failure of standard alternatives.

Medicare covers testosterone therapy under Part D for beneficiaries with a documented diagnosis of hypogonadism. Coverage and cost-sharing vary by plan formulary, but generic injectables are generally accessible at low copays for Medicare beneficiaries. The Medicare Part D coverage gap, colloquially the donut hole, can affect patients on branded formulations who reach the coverage threshold mid-year, though ACA adjustments have reduced this exposure in recent years.

Men who do not meet strict diagnostic criteria for hypogonadism, including those who have borderline testosterone levels or symptoms of andropause without confirmatory lab values below threshold, may find that their therapy is not covered regardless of clinical rationale. This group, which includes many men in their 40s and 50s seeking optimization rather than replacement in the strict sense, typically pays out of pocket.

Telehealth vs. Traditional Clinic: The Full Cost Comparison

The structural economics of telehealth-delivered TRT are distinct from those of a traditional urology or endocrinology practice in ways that consistently favor the patient on cost. The comparison requires examining four components: the consultation and management fee, the pharmaceutical cost, the laboratory cost, and the effective time cost to the patient.

In a traditional specialist model, a new patient seeking evaluation for low testosterone will typically wait several weeks for an initial appointment, pay a specialist office visit copay of $50 to $150 with insurance, or $200 to $500 without, obtain baseline labs through the practice's affiliated laboratory, return for a follow-up to discuss results, receive a prescription routed to a retail pharmacy, and schedule quarterly or biannual monitoring visits. Each visit carries a time cost and a copay, and the system is optimized for in-person care rather than efficient ongoing management of a stable chronic condition.

In a telehealth model, the same patient completes an asynchronous intake and symptom assessment, orders labs at a direct-to-consumer price or through the platform's lab partner, consults with a physician or nurse practitioner via video or messaging, receives a prescription routed directly to a compounding or mail-order pharmacy, and manages ongoing monitoring through digital lab uploads or platform-ordered draws. The monthly program fee is fixed and predictable, and geographic barriers to specialist access are eliminated.

For men in regions with limited specialist access, telehealth-delivered TRT is not merely a convenience option. It is often the only realistic path to timely, supervised care.

Healthspan's Men's Hormone Health program is built on this telehealth model, providing physician-supervised testosterone therapy with transparent pricing and ongoing management support. The program's structure is designed to maintain clinical rigor without the overhead that inflates the cost of equivalent care in a traditional office setting.

The trade-off in a telehealth model is the absence of in-person physical examination, which is a relevant consideration for men who have not recently been evaluated by a physician. The initial assessment should still include a recent physical exam and the digital rectal exam or PSA screening appropriate to the patient's age and risk profile. Many telehealth platforms require patients to have had a recent in-person exam or will coordinate referral for those components that cannot be conducted remotely. Men who enter a telehealth TRT program without a recent clinical evaluation should not view the telehealth model as a substitute for that foundational assessment.

Compounded vs. FDA-Approved: The Regulatory and Cost Divide

The tension between FDA-approved branded testosterone products and compounded testosterone preparations is not merely about price. It reflects a fundamental division in how the United States regulatory system handles pharmaceutical manufacturing, and the practical implications for patients are significant.

FDA-approved testosterone products have undergone rigorous clinical trials demonstrating safety, efficacy, and manufacturing consistency. The agency's oversight extends to every lot of the finished product. Compounded preparations made by 503A compounding pharmacies are prepared pursuant to individual prescriptions and are not subject to the same pre-market review process. However, 503B outsourcing facilities, a category created by the Drug Quality and Security Act of 2013, produce compounded products in bulk under FDA-inspected conditions that more closely approximate those of pharmaceutical manufacturers [5].

The practical clinical significance of this distinction is that the pharmaceutical quality of testosterone from a reputable 503B facility is generally regarded by clinicians as comparable to generic injectable testosterone from a traditional manufacturer, at a lower per-unit cost. The FDA has periodically taken enforcement action against 503A compounding pharmacies that violated good practice standards, which underscores the importance of using compounding pharmacies with verified quality credentials rather than selecting on price alone [5].

From a cost standpoint, compounded testosterone cypionate injection is typically the least expensive available option, often by a factor of two to four compared to the branded FDA-approved equivalent. For topical testosterone, compounded cream is typically less expensive than branded gel while offering comparable clinical outcomes for most patients. The cost savings from compounding are most meaningful for patients without insurance coverage who would otherwise pay full retail for branded formulations.

Practical Cost Summary: What to Expect in 2025

Synthesizing the above across delivery methods, here is what men considering testosterone replacement therapy can expect to pay in 2025 on an annual basis, including pharmaceuticals and monitoring but excluding management fees where those vary by setting.

Injectable testosterone cypionate, self-administered weekly, represents the lowest total pharmaceutical cost: roughly $150 to $600 per year for the drug and supplies. Adding two to four lab monitoring draws per year at $50 to $200 each without insurance brings the total monitoring cost to $100 to $800 annually. A telehealth management program typically adds $360 to $1,200 per year in program fees. All-in, a well-managed injectable TRT program with telehealth oversight and regular monitoring typically costs $600 to $2,600 annually without insurance, or substantially less when insurance covers the pharmaceutical component.

Topical testosterone gel or cream, whether compounded or generic, carries pharmaceutical costs of $500 to $1,800 per year depending on the formulation. Adding monitoring and management brings the total to approximately $1,000 to $3,600 annually without insurance.

Testosterone patches, using generic formulations, run approximately $1,000 to $2,400 per year in pharmaceutical costs, with total annual costs including monitoring and management in the $1,600 to $4,200 range.

Testosterone pellets cost $1,000 to $4,000 annually for the insertion procedures alone, with monitoring adding $200 to $800 per year. Total annual costs range from $1,200 to $4,800 without insurance.

Oral testosterone undecanoate remains among the most expensive options at $8,400 to $10,800 annually at retail pharmacy prices without insurance. With insurance coverage, cost-sharing brings this to $360 to $1,200 annually at typical copay tiers.

Fertility Preservation and TRT: An Additional Cost Consideration

One cost that rarely appears in TRT pricing guides is the expense associated with fertility preservation or management for men of reproductive age. Exogenous testosterone suppresses luteinizing hormone and follicle-stimulating hormone, the pituitary signals that drive both testosterone production and sperm synthesis in the testes [2]. Men who do not account for this suppression before starting TRT may find that spermatogenesis is compromised within months of beginning treatment.

Recovering spermatogenesis after testosterone suppression typically requires months of treatment with hCG (human chorionic gonadotropin), clomiphene, or enclomiphene following TRT discontinuation, and recovery is not guaranteed in all men [2]. For men who wish to preserve fertility, options include delaying TRT in favor of enclomiphene monotherapy, adding hCG to a TRT protocol, or banking sperm before beginning therapy. Sperm banking typically costs $500 to $1,000 for the collection and initial storage, with annual storage fees of $300 to $500 thereafter.

These fertility-related costs are not hypothetical concerns for the median TRT candidate. Men in their 30s who present with low testosterone and have not completed their families should factor this dimension into their cost-benefit analysis before initiating therapy. The Enclomiphene protocol offers a clinically validated alternative for this population: stimulating endogenous testosterone production by blocking estrogen feedback at the pituitary, which preserves the gonadal axis and spermatogenesis while improving testosterone levels.

Conclusion: Matching Cost to Clinical Reality

The question of testosterone replacement therapy cost does not have a single answer, and any platform or provider that quotes one price without asking about delivery method preference, insurance status, and monitoring needs is obscuring the full picture. What this breakdown reveals is that the cost differential between the least and most expensive TRT options is not marginal: it spans an order of magnitude. A man on compounded injectable testosterone managed through a telehealth platform and monitoring labs twice annually might spend $800 per year in total. A man on branded patch therapy with traditional specialist oversight and frequent office visits might spend $8,000 for identical clinical outcomes.

The clinically relevant question is not which option is cheapest, but which option delivers the best outcome per dollar invested across the full program. That calculation depends on adherence, pharmacokinetic fit, monitoring access, and physician quality as much as it depends on the drug price. Injectable testosterone is cheap, but it requires the patient to be comfortable with self-injection and to understand dosing titration. Pellets are expensive, but they remove the adherence variable entirely for men who struggle with consistent daily or weekly routines.

What the data consistently support is that the telehealth model significantly reduces the management and overhead costs of TRT without degrading clinical quality for stable patients on established protocols. The emergence of transparent, physician-supervised programs like Healthspan's Men's Hormone Health offering reflects a broader structural shift in how specialized hormonal care is delivered, one that is particularly relevant for the growing number of men who recognize low testosterone not as a discrete disease to be treated but as a modifiable driver of metabolic aging to be managed intelligently over the long term. For those men, the cost of TRT is not just an expense. It is an investment in the quality and trajectory of the years ahead.